Digitisation | December 16, 2025
Accenture invests in Ryght AI to revolutionize clinical trials
Ryght AI tackles these hurdles with its AI Site Twin platform
Ryght AI tackles these hurdles with its AI Site Twin platform
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
The Healey ALS Platform Trial is a multicenter, double-blind, placebo-controlled
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
The initiative aims to connect startups and tech companies with its business units,
Subscribe To Our Newsletter & Stay Updated
